WO2016033899A1 - Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu - Google Patents
Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu Download PDFInfo
- Publication number
- WO2016033899A1 WO2016033899A1 PCT/CN2014/093562 CN2014093562W WO2016033899A1 WO 2016033899 A1 WO2016033899 A1 WO 2016033899A1 CN 2014093562 W CN2014093562 W CN 2014093562W WO 2016033899 A1 WO2016033899 A1 WO 2016033899A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- weight
- scalp
- dandruff
- present
- Prior art date
Links
- 210000004761 scalp Anatomy 0.000 title claims abstract description 132
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 100
- 230000004888 barrier function Effects 0.000 claims abstract description 36
- 210000002374 sebum Anatomy 0.000 claims abstract description 29
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims abstract description 21
- BVWAOXGNDVRQSO-UHFFFAOYSA-N 3-hydroxy-2,6-dihydro-1h-pyrimidine Chemical compound ON1CNCC=C1 BVWAOXGNDVRQSO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 claims abstract description 15
- CFXSFDXXYYHZFU-UHFFFAOYSA-N 2-hydroxybenzoic acid;2-(trimethylazaniumyl)acetate Chemical compound C[N+](C)(C)CC(O)=O.OC(=O)C1=CC=CC=C1[O-] CFXSFDXXYYHZFU-UHFFFAOYSA-N 0.000 claims abstract description 11
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims abstract description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical group NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 30
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 15
- 229960000458 allantoin Drugs 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000008591 skin barrier function Effects 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 239000011814 protection agent Substances 0.000 abstract 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 241000555676 Malassezia Species 0.000 description 15
- 150000002632 lipids Chemical group 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 14
- 210000000434 stratum corneum Anatomy 0.000 description 14
- 244000005700 microbiome Species 0.000 description 13
- 235000019156 vitamin B Nutrition 0.000 description 13
- 239000011720 vitamin B Substances 0.000 description 13
- 229930003270 Vitamin B Natural products 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 11
- 239000002453 shampoo Substances 0.000 description 11
- 241000202807 Glycyrrhiza Species 0.000 description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 10
- 229940010454 licorice Drugs 0.000 description 10
- 208000003251 Pruritus Diseases 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- 230000036572 transepidermal water loss Effects 0.000 description 8
- 206010040844 Skin exfoliation Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000000622 irritating effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- -1 derivative of tetrahydropyrimidine hydroxytetrahydropyrimidine Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000035618 desquamation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 3
- 229910000338 selenium disulfide Inorganic materials 0.000 description 3
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 description 3
- 229960005265 selenium sulfide Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000011280 coal tar Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N 2-Methyl-4-carboxy-3,4,5,6-tetrahydropyrimidine Chemical compound CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001270131 Agaricus moelleri Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- 241000206596 Halomonas Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- WEOXIOKZYVXZRP-UHFFFAOYSA-N N=1C(NC(C1)=O)=O.NC(=O)N Chemical compound N=1C(NC(C1)=O)=O.NC(=O)N WEOXIOKZYVXZRP-UHFFFAOYSA-N 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 229940122511 Sebum inhibitor Drugs 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940086207 head & shoulders Drugs 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000005326 tetrahydropyrimidines Chemical class 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Definitions
- the invention belongs to the field of daily chemistry, and in particular relates to a composition for regulating dander by balancing sebaceous sebaceum.
- the dandruff is born on the scalp and is a large amount of desquamation caused by excessive proliferation of scalp keratinocytes. About 60% of adults in China suffer from dandruff problems to varying degrees, and 15% of them are very serious. At present, although the personal care products claimed by the anti-dandruff function are endless, 70% of the people who use the anti-dandruff products think that the effect is not satisfactory.
- dandruff The pathogenesis of dandruff has not yet been clarified. There are several theories about the cause of dandruff, the most important of which is the mechanism of action of Malassezia. Numerous studies have shown that Malassezia is closely related to the occurrence and severity of dandruff. The proliferation of Malassezia on the scalp causes excessive proliferation of the stratum corneum of the scalp, which causes the stratum corneum cells to fall off in the form of white or gray scales. This shedding scaly is dandruff.
- Malassezia belongs to the yeast single-cell fungus and survives by consuming fatty acids in sebum. It is lipid-dependent and easily grows on sebum-rich skin.
- the result of an inflammatory reaction caused by Malassezia is the excessive proliferation of scalp cells in the scalp, usually accompanied by abnormalities in the scalp ultrastructure. Occurrence includes incomplete keratinization, abnormal keratinous membrane, lipids contained in scalp cells and between cells.
- the stratum corneum stripping agent removes damaged epidermal cells from the stratum corneum by desquamation to achieve dandruff removal.
- Early anti-dandruff agents such as salicylic acid, sulfur, and shampoos containing coal tar, fall into this category.
- the odor of such products is poor and irritating, and its effect is not superior to other dandruff products, and long-term application will also destroy the epidermal structure to disturb the balance of the epidermis, which has certain damage to the skin.
- the third type is anti- Microbial preparations achieve the purpose of inhibiting dandruff by inhibiting or destroying the formation of microbial entities, and their anti-dandruff action depends on the number of Malassezia that can reduce or control the scalp.
- antimicrobial preparations have been widely used in anti-dandruff products.
- ketoconazole, clomiprazole and pyrithione in shampoos for dandruff in pharmacies or supermarkets are all antimicrobial agents.
- Shampoos containing ketoconazole and clomiprazole are mostly sold in hospitals and pharmacies, such as shampoos such as Picker.
- Anti-dandruff products containing Zinconazole ZPT are widely sold in shopping malls and barbershops, such as Head & Shoulders, Avon and other anti-dandruff shampoos, but also have poor solubility and strong degreasing ability.
- the current mainstream products on the market are the number of Malassezia that inhibits the growth of microorganisms.
- the overall anti-dandruff effect is also good, but the only drawback is that the main anti-dandruff agent of anti-microbial effect, such as Zinconazole zinc ZPT, has a relatively strong degreasing property, while killing Malassezia
- the scalp keratin barrier function is destroyed to varying degrees (see US patent PAT.NO.5053222.
- composition of the present invention is composed of a scalp sebum regulator and a scalp barrier protectant, and restores and enhances the barrier function of the scalp by the action of both to reduce the effect of dandruff.
- An anti-dandruff composition comprising, in addition to a cosmetically acceptable carrier, a scalp barrier protectant and a scalp sebum regulating agent, the components and contents of which are as follows:
- compositions of N-palmitoylethanolamine Between 0.001% and 1.0% by weight of the composition of N-palmitoylethanolamine and 100% by weight of the composition a composition of 0.01%-20% N-acetylethanolamine, and the weight ratio of the two is 1:100;
- composition By weight of the composition is from 0.1% to 15% of trimethylglycine and salicylate of the composition by weight of 0.05% to 3% of vitamin B 12.
- the anti-dandruff composition of the present invention wherein the N-palmitoylethanolamine content is optimized to be from 0.005% to 0.5% by weight of the composition; and the N-acetylethanolamine is from 0.05% to 10% by weight of the composition. And the weight ratio of N-palmitoylethanolamine and N-palmitoylethanolamine was further optimized to 1:50.
- Anti-dandruff compositions of the present invention wherein the content of trimethylglycine salicylate optimization of the composition by weight of 0.2% to 8%; vitamin B 12 weight percent of the composition is 0.1% -2%.
- the skin barrier protectant in the anti-dandruff composition of the present invention is preferably hydroxytetrahydropyrimidine in an amount of from 0.05% to 1% by weight based on the total weight of the composition.
- the anti-dandruff composition of the present invention further comprises from 0.05% to 0.5% by weight of the composition of allantoin and 5% by weight of the composition.
- the allantoin content is optimized to be from 0.08% to 0.2% by weight of the composition.
- An anti-dandruff composition having a composition and content of:
- N-acetylethanolamine in an amount of 0.625% by weight of the composition
- the anti-dandruff composition of the present invention adopts a method of non-traditional inhibition and killing of Malassezia, and achieves synergy between scalp sebum regulation and scalp barrier protection, and the synergistic cooperation between the two can help the scalp
- the normal thickness of the water-lipid membrane is restored, and the scalp lipid dynamic balance is established, and the scalp barrier function is restored to reduce the dandruff.
- the anti-dandruff technique of the present invention can be applied to hair dandruff conditioner, anti-dandruff shampoo, etc., and the anti-dandruff composition of the present invention only explains the advantage of the anti-dandruff of the present invention in the form of a lotion formulation.
- Oily dandruff is dandruff produced by oily hair. It is large in block shape and easily adheres to the scalp and hair. It is less likely to fall off the shoulder and the color is partial. yellow. Oily dandruff is caused by excess oil irritating the scalp and inducing excessive reproduction of harmful bacteria (such as Maize), thereby destroying the balance of the scalp, causing abnormal metabolism of the scalp and causing the increase of dead skin, resulting in a large amount of dandruff.
- harmful bacteria such as Maize
- the scalp oil has the function of protecting the scalp barrier, moisturizing and protecting the scalp and hair. Too much can not be done, so it is very important to find an effective way to regulate the scalp sebum.
- the effect of the scalp sebum regulation of the present invention is to establish a balance between the oil and the dryness of the scalp. Over-tempering and removing scalp lipids while preventing excessive keratinization or shedding of the scalp, the previous regulation of scalp oil is through exfoliation of the stratum corneum and exfoliation of the stratum corneum by removing the damaged epidermal cells in the stratum corneum by desquamation. And to achieve the effect of removing dandruff. Early anti-dandruff agents, such as salicylic acid, sulfur, and shampoos containing coal tar, fall into this category.
- the invention has undergone a large number of experiments, and the synergistic action of the scalp sebum regulator and the scalp barrier protectant acts to reduce and inhibit dandruff.
- the scalp sebum regulator of the present invention uses a derivative of salicylic acid and vitamin B.
- the substance, salicylic acid derivative is trimethylglycine salicylate, which can gently balance scalp sebum
- vitamin B is made of vitamin B 12
- vitamin B 12 can well nourish the scalp and inhibit excessive scalp.
- the combination of a salicylic acid derivative and vitamin B plays a key role in regulating the sebum of the scalp.
- the invention has found through a large number of experiments that the scalp barrier protection effect can be achieved by the endogenous lipid component of the skin and the extreme halophilic solute.
- the endogenous lipid components in the skin include N-palmitoylethanolamine and N-acetylethanolamine, and the extreme halophilic solute is tetrahydropyrimidine and a derivative of tetrahydropyrimidine, hydroxytetrahydropyrimidine, which restores and enhances the scalp barrier function.
- the invention is based on the joint efforts of Lafang Jiahua Co., Ltd., the Institute of Microbiology of the Chinese Academy of Sciences and BASF of Germany, to study the problem of dandruff from the relationship between scalp health, scalp microenvironment and dandruff, and the present invention is more specific to the study.
- the present invention starts from the root of dandruff, that is, the scalp, and restores and strengthens the function of the scalp stratum corneum barrier, so that the scalp can effectively resist the invasion of bacteria and fungi, thereby further preventing and reducing.
- the production of dandruff is based on the joint efforts of Lafang Jiahua Co., Ltd., the Institute of Microbiology of the Chinese Academy of Sciences and BASF of Germany, to study the problem of dandruff from the relationship between scalp health, scalp microenvironment and dandruff, and the present invention is more
- the anti-dandruff composition of the present invention achieves the effect of inhibiting and reducing dandruff by regulating the balance of scalp sebum and enhancing the function of the scalp barrier.
- the anti-dandruff composition contains, in addition to a cosmetically acceptable carrier, the active ingredients as follows:
- the scalp barrier protectant consists of the endogenous lipid component of the skin and the halophilic solute of the extreme:
- the endogenous lipid component of the skin is 0.001%-1.0% by weight of the composition of N-palmitoylethanolamine and 0.01%-20% by weight of the composition of N-acetylethanolamine, and the weight ratio of the two is 1 :100; the extreme halophilic solute is one of tetrahydropyrimidine and hydroxytetrahydropyrimidine,
- the scalp barrier protective agent in the anti-dandruff composition of the present invention is composed of an endogenous lipid component of the skin and an extremely halophilic solute: wherein the skin endogenous lipids include N-palmitoylethanolamine and N-acetylethanolamine.
- N-palmitoylethanolamine has a molecular formula of C 18 H 37 NO 2 , a molecular weight of 299.49 g mol -1 and a melting point of 59 to 60 ° C (138 to 140 ° F; 332 to 333 K).
- N-acetylethanolamine has the formula: CH 3 -CO-NH-C 2 H 4 OH, the substance is a viscous liquid at room temperature, density (DIN/20 degrees Celsius) 1.12, molecular weight 103, boiling point 155 degrees Celsius (5mmHg), density 1.052g/cm 3 .
- the skin endogenous lipid component is further optimized to be 0.005%-0.5% by weight of the composition of N-palmitoylethanolamine and 0.05%-10% by weight of the composition. N-acetylethanolamine.
- the weight ratio of N-palmitoylethanolamine and N-palmitoylethanolamine in the present invention is further optimized to be 1:50.
- the moisturizing factor in human skin including lactic acid, sodium lactate, hyaluronic acid, urea, amino acid, lecithin, etc., is an indispensable physiological function moisturizing factor in human skin.
- the invention relates to a moisturizing agent extracted from a high salt-tolerant and high-cold microorganism (extreme halophilic bacteria) in an extreme environment.
- extreme environment On Earth, the environment outside the biosphere where humans live is called the extreme environment, which means that the physical and chemical conditions reach or exceed the life tolerance range.
- Microorganisms that can grow in extreme environments are called extreme microorganisms such as halophilic microorganisms.
- Hot microorganisms, psychrophilic microorganisms have been acidophilic microorganisms, etc. It is worth noting that these extreme microorganisms not only “tolerate” these extreme environments, but also require one or more extreme conditions for better growth and reproduction, among which moderate Halophilic microorganisms are one of them.
- the present invention is applied to a microorganism that grows in an extreme environment, that is, a high salt and alpine environment.
- Solute-tetrahydropyrimidine and its derivative hydroxytetrahydropyrimidine (Ph.D., 2005.11.16 Zhao Baisuo) tetrahydropyrimidine and hydroxytetrahydropyrimidine as stabilizers extracted from the genus Salicorella and C. It protects microorganisms from enzymes, DNA and macromolecules. It acts against microbes in extreme environments, resists high salt, resists drying, freezes and prevents heat denaturation. It is a molecular chaperone and protection for extreme microorganisms to survive in extreme environments. God.
- the application of tetrahydropyrimidine and hydroxytetrahydropyrimidine in cosmetics has also received more and more attention. It was developed by Merck and the Institute of Microbiology of the Chinese Academy of Sciences.
- the solute component in the halomonas elongate of the present invention is a tetrahydropyrimidine or a derivative of tetrahydropyrimidine hydroxytetrahydropyrimidine.
- Tetrahydropyrimidine chemical name 2 methyl-1,4,5,6-tetrahydropyrimidine 4carboxylic acid, molecular formula: C 6 H 10 N 2 O 2 , molecular weight: 142.2 g / mol, LD50 (oral-rat 2200mg/kg, white powder, SIGMA-ALDRICH, or developed by the Institute of Microbiology, Chinese Academy of Sciences.
- the halophilic solute is preferably hydroxytetrahydropyrimidine, and the hydroxytetrahydropyrimidine according to the present invention is 0.01% to 2% by weight of the composition, further optimized to be 0.05% to 1%.
- Salicylic acid derivatives salicylic acid as a scalp sebum inhibitor and a scalp exfoliating agent have a certain irritating effect on the scalp, and often have a destructive effect on the scalp barrier. Therefore, the present invention uses a derivative of salicylic acid, namely, a top three Glycine hydrochloride.
- Trimethylglycine salicylate and ⁇ -hydroxy acid (BHAs) in salicylic acid are similar to ⁇ -hydroxy acids (AHAs), have the function of accelerating the exfoliation of squamous keratinocytes, and are more irritating than ⁇ -hydroxy acids (AHAs). ) much lower; trimethylglycine in betaine has moisturizing, increasing skin elasticity and hydration, Substructures have both cationic and anionic charges, while human skin, including the scalp and hair, are all negatively charged under normal physiological conditions, so they contain positively charged molecules that have a natural affinity for the scalp and hair.
- the trimethylglycine salicylic acid ester used in the present invention perfectly combines the advantages of salicylic acid extracted from willow bark and trimethylglycine extracted from betaine, and forms a unique structure of salicylic acid, which is mild. Adjusting the thickness of the scalp stratum corneum to a relatively ideal state, which contributes to the formation and improvement of the scalp barrier function, and has a gentle regulation effect on the scalp and hair lipids.
- the scalp sebum regulator of the present invention is trimethylglycine salicylate in an amount of 0.1% to 15% by weight of the composition, and is further optimized to be 0.2% to 8% by weight.
- Vitamins including vitamin A, vitamin C, vitamin D, and vitamin B are all participants in the physiological functions of the human body and play different roles in human skin and metabolism. Among them, B vitamins contain many types. The role in hair and scalp and its physiological functions is also prominent. Among them, B vitamins include B 1 , B 2 , B 3 , B 5 , B 6 , B 12 , etc. According to previous applications and literature reports, the role of provitamin B 5 in scalp and hair nourishment is a recognized fact. , Tanno O, Ota Y, Kitamura N, et al. Br J Dermatol. 2000; 143: 524-531. and J Cosmet Laser Ther. 2006 Jun; 8(2): 96-101. Reported that vitamin B 3 has A function of enhancing the skin barrier and controlling the secretion of oil from the skin, U.S. Patent No. 6,110,472 discloses a cosmetic composition containing vitamin B 12 for the treatment of abnormal scalp detachment.
- the scalp sebum regulating agent of the present invention has a range of vitamin B 1 , vitamin B 2 , vitamin B 3 , vitamin B 6 , provitamin B 5 , and vitamin B 12 .
- the vitamin B of the present invention is further screened for vitamin B 3 , vitamin B 6 and vitamin B. 12 and further preferred vitamin B 12 .
- the vitamin B 12 of the present invention comprises from 0.05% to 3% by weight of the composition, and is further optimized to be from 0.1% to 2%.
- Scalp soothing agent scalp soothing agent includes allantoin, licorice flavonoids, dipotassium glycyrrhizinate, etc.
- dipotassium glycyrrhizinate white fine powder, sweet taste, and medicine, can activate corticosteroids (inhibition of metabolism) Enzyme).
- corticosteroids inhibitor of metabolism
- the above specifications are UV ⁇ 98%, and HPLC ⁇ 76% (refers to the active ingredient of glycyrrhizic acid).
- Dipotassium glycyrrhizinate has a chemical formula of C 42 H 60 K 2 O 16 , a molecular weight of 899.1128, and a pH of 5-6.
- Licorice flavonoids are natural ingredients extracted from specific varieties of licorice, licorice flavonoids such as licorice, licorice and aspartame, mannitol, etc., and the compound extracted from licorice - licorice flavonoids in beauty cosmetics
- licorice flavonoids also inhibit tyrosinase activity, scavenging oxygen base, which has anti-inflammatory, anti-allergic effects.
- Flavonoids flavonoids brown-red thick liquid, insoluble in water and various oil esters, soluble in ethanol, propylene glycol, glycerin and some organic solvents.
- allantoin is an amphoteric compound, it can form a complex combination of various substances to keep the skin moist, moisturized and soft. It is a special additive for cosmetics such as beauty salons. It is widely used in freckle cream, acne, shampoo, soap, Additives such as toothpaste, shave lotion, hair conditioner, astringent, anti-sweat deodorant lotion, etc. Cosmetics containing allantoin have the functions of protecting tissues, hydrophilicity, water absorption and preventing water dispersion;
- the scalp soothing agent in the present invention is preferably allantoin.
- allantoin is mainly used for its soothing action on the scalp, and has a softening effect on the stratum corneum of the scalp. Helps the scalp to build a water-lipid film to enhance the hydration of the skin surface and reduce the loss of transepidermal water, thereby synergistically enhancing the barrier function of the skin.
- allantoin comprises from 0.05% to 0.5% by weight of the composition, and is further optimized to be from 0.08% to 0.2%.
- the polyol may be 1,3 butanediol, propylene glycol, glycerin (glycerol), 1,2-pentanediol, ethanol, etc., and glycerin is preferred in the present invention, and the amount used is composition.
- the weight percentage is from 1% to 10% and is further optimized to be from 2% to 8% by weight of the composition.
- Thickeners which can be used in the present invention include acrylic acid polymers, carbopol resins, hydroxyethyl cellulose, xanthan gum, etc., and the use of xanthan gum in the present invention is preferably used in an amount of 0.02 by weight of the composition. % to 0.5% and further optimized to 0.05% to 0.3% by weight of the composition.
- the chelating agent which can be used in the present invention includes disodium edetate and tetrasodium ethylenediaminetetraacetate.
- disodium edetate is preferably used in an amount of 0.01% by weight of the composition. To 0.1%, and further optimized to be from 0.02% to 0.1% by weight of the composition.
- preservatives which can be used in the present invention include parabens, diazoalkyl ureas, phenoxyethanol, etc., and phenoxyethanol is preferably used in the present invention, and the amount used is 0.1% to 1.0% by weight of the composition. %, and further optimized to account for 0.5% to 0.8% by weight of the composition.
- An anti-dandruff composition of the present invention which modulates sebum balance of the scalp can be prepared by any known or otherwise effective technique suitable for providing a hair care composition, and the process of the present invention comprises conventional formulation and mixing techniques. Adding disodium edetate, allantoin, xanthan gum, glycerin, etc. to the components of the present invention in deionized water by weight, heating to 80 degrees and stirring to dissolve until transparent, and then stirring while cooling, when the temperature When reduced to 45 degrees, add vitamin B 12 , N-palmitoylethanolamine, N-acetylethanolamine, hydroxytetrahydropyrimidine and trimethylglycine salicylate, respectively, by stirring, dissolve, and finally add preservatives and flavors. , a pigment, a pH adjuster, and the pH adjuster of the anti-dandruff composition is adjusted to 7.
- the anti-dandruff composition of the present invention for regulating the sebum balance of the scalp is used in the conventional manner of cleaning and conditioning the scalp, and mainly comprises the following steps:
- anti-dandruff compositions of the present invention are non-limiting examples.
- the examples are given for the purpose of illustration only, and are not to be construed as limiting the scope of the invention. In these examples, all concentrations are by weight unless otherwise stated.
- the efficacy evaluation of the present invention is carried out based on the technical means employed in the anti-dandruff composition of the present invention.
- the anti-dandruff composition of the invention adopts the technical scheme of non-traditional inhibition and killing of Malassezia, but is realized by the synergistic action of scalp sebum regulation and scalp barrier protection, and the synergistic cooperation between the two can help scalp recovery
- the normal thickness of the water lipid film establishes the dynamic balance of the scalp lipid and restores the scalp barrier function to reduce the dandruff. Therefore, in the efficacy test, the protective effect of the scalp barrier function was examined by the instrument TEWL method and the evaluation of the itching and anti-dandruff effect of the sensory evaluation test example.
- the instrument test method is to test the value of TEWL of transepidermal water loss in the scalp.
- the larger the TEWL value the faster the loss of water in the scalp, indicating that the barrier effect of the scalp is worse. Conversely, the smaller the TEWL value of the test indicates that the scalp remains moisture. The ability to be strong indicates that the scalp barrier function is enhanced.
- the measuring instrument used in the present invention model: Delfin/VapoMeter, measuring range: 3-200 g/m 2 h. Test site: top position.
- the sensory evaluation method mainly tests the sensory effect of the embodiment on the anti-dandruff, and the sensory evaluation method of the complex head is: distributing the prepared embodiment to the tester, and the living habits in the process of using the sample of the embodiment of the invention
- the shampoo brands used did not change. None of the samples of the examples were used for four weeks, and the testers scored according to their own feelings, wherein the antipruritic effect was based on the start of the itching. It is scored by the degree of itching, and the anti-dandruff effect is scored according to the amount and size of the dandruff.
- the tester used the anti-dandruff composition sample, which was used after shampooing, and was used continuously for four weeks and three times a week.
- the first day of the week begins to calculate the start, according to the occurrence of itching and the onset of dandruff, if the first day of the fifth week begins to score 1 point, the next day 2 points, and so on If the itch starts on the seventh day, score 7 points.
- the scoring standard uses a 7-point scale, with 1 being the worst and 7 being the best. The higher the score, the better the better.
- Table 1 The higher the score, the better the better.
- the method of use was based on the method of use of the present invention, and the 7th day, the 14th day, the 21st day, the 28th, respectively.
- the TEWL value of the scalp was measured (averaged) in days and scored according to the above requirements to observe the degree of dandruff;
- the present inventions I to X were respectively used, and the method of use was determined according to the method of use of the present invention, and the scalp was measured on the 7th day, the 14th day, the 21st day, and the 28th day, respectively.
- control blank 1 of the present invention was used as required, and the percutaneous water loss value of the scalp on the 7th day after use and the transepidermal water loss value on the 28th day after use were measured, and the scalp transepidermal water loss value on the 28th day was measured.
- the decrease of 0.8% indicates that the value of transepidermal water loss of the scalp is not changed after the use of blank 1;
- the control blank 2 of the present invention measures the transepidermal water loss value of the scalp on the 7th day after use and the scalp on the 28th day after use.
- Percutaneous water loss values showed that the transepidermal water loss value of the scalp decreased by 1.4% on the 28th day, indicating that the value of transepidermal water loss of the scalp did not change much after using the blank 2, which was equivalent to no change.
- the measured transepidermal water loss value of the scalp was reduced to a different extent on the 28th day than the seventh day (for example, in the example VI with the least reduction value, the TEWL was reduced by 15.7%, such as Example VII with the largest reduction value, TEWL decreased by 34.6%), indicating that the scalp barrier function was enhanced after using the embodiment of the present invention; and the antipruritic effect and the anti-dandruff effect obtained by the sensory evaluation method were obtained with blank 1 and blank 2
- the sensory effect contrast has been greatly improved, indicating that the present invention inhibits and reduces dandruff by regulating the balance of scalp sebum and the enhancement of scalp barrier function without containing bacteriostatic and bactericidal agents.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Cette composition antipelliculaire comprend un support acceptable sur le plan cosmétique, un agent protecteur du cuir chevelu et un agent régulateur de sébum pour le cuir chevelu, lequel comprend une N-palmitoyl-éthanol amine dont le poids correspond à 0,001-1,0 % de la composition, une N-acétyl éthanolamine dont le poids correspond à 0,01-20 % de la composition et une tétrahydro-pyrimidine ou une hydroxy-tétrahydro-pyrimide dont le poids correspond à 0,01-2 % de la composition, le rapport en poids de N-palmitoyl-éthanol amine et N-acétyl éthanolamine étant de 1 : 100. L'agent régulateur du sébum du cuir chevelu correspond, exprimé en poids de la composition, à 0,1-15 % de triméthyl glycine salicylate et à 0,05-3 % de vitamine B12.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410452863.2 | 2014-09-05 | ||
CN201410452863.2A CN104287982B (zh) | 2014-09-05 | 2014-09-05 | 一种调节头皮油脂平衡的去屑组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016033899A1 true WO2016033899A1 (fr) | 2016-03-10 |
Family
ID=52308102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/093562 WO2016033899A1 (fr) | 2014-09-05 | 2014-12-11 | Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104287982B (fr) |
WO (1) | WO2016033899A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109796367B (zh) * | 2019-03-29 | 2022-02-15 | 广东工业大学 | 一种n-脂肪酰基乙醇胺产品的制备方法及其应用 |
CN110585046A (zh) * | 2019-10-12 | 2019-12-20 | 曹志军 | 一种去屑止屑防脱发增发组份及产品 |
CN112656709A (zh) * | 2021-01-06 | 2021-04-16 | 华熙生物科技股份有限公司 | 皮肤护理组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1602835A (zh) * | 2003-08-06 | 2005-04-06 | 花王株式会社 | 气雾剂化妆品 |
CN102227208A (zh) * | 2008-11-07 | 2011-10-26 | 科学发展实验室 | 用于治疗和预防瘙痒症的包含鳄梨肽提取物的药物或皮肤病学组合物 |
CN103417394A (zh) * | 2013-05-06 | 2013-12-04 | 上海玉华生命科技发展有限公司 | 一种高效祛眼皱的含Cu、Zn-rhSOD脂质体组合物 |
-
2014
- 2014-09-05 CN CN201410452863.2A patent/CN104287982B/zh active Active
- 2014-12-11 WO PCT/CN2014/093562 patent/WO2016033899A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1602835A (zh) * | 2003-08-06 | 2005-04-06 | 花王株式会社 | 气雾剂化妆品 |
CN102227208A (zh) * | 2008-11-07 | 2011-10-26 | 科学发展实验室 | 用于治疗和预防瘙痒症的包含鳄梨肽提取物的药物或皮肤病学组合物 |
CN103417394A (zh) * | 2013-05-06 | 2013-12-04 | 上海玉华生命科技发展有限公司 | 一种高效祛眼皱的含Cu、Zn-rhSOD脂质体组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN104287982A (zh) | 2015-01-21 |
CN104287982B (zh) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101420599B1 (ko) | 항여드름제를 함유하는 조성물 및 이의 용도 | |
JPWO2004016236A1 (ja) | 化粧料 | |
US20180360712A1 (en) | Cosmetic composition and use thereof | |
JP2014521671A (ja) | 皮膚および毛髪の外観を改善するためのスフィンガニンの使用 | |
CN111372595A (zh) | 治疗皮肤的方法和组合物 | |
CN116265007A (zh) | 一种防脱控油舒缓精华液及其制备方法 | |
KR101494661B1 (ko) | 흑마늘박 발효물을 포함하는 두피 또는 모발 케어용 조성물 및 그 제조방법 | |
CN103347507A (zh) | 用于治疗痤疮的褪黑激素以及抗微生物剂或抗菌剂 | |
KR20090054777A (ko) | 피부의 pΗ 조절용 조성물 및 이를 포함하는 화장품 | |
US10420962B2 (en) | Organic hair formulation and treatment | |
JP2004091376A (ja) | 表皮角化正常化剤及びこれを含有する皮膚外用剤 | |
WO2016033899A1 (fr) | Composition antipelliculaire permettant de rétablir l'équilibre du cuir chevelu | |
KR20200073970A (ko) | 수딩 크림 및 이의 제조 방법 | |
JP2017193506A (ja) | 皮膚化粧料 | |
JP7305161B2 (ja) | 皮膚化粧料 | |
CN116509774B (zh) | 一种含青蒿提取物的去屑洗发制剂及其制备方法 | |
JP5455292B2 (ja) | 皮膚外用組成物 | |
JPH03112912A (ja) | 化粧料組成物 | |
JP6052181B2 (ja) | 化粧料 | |
KR20150116504A (ko) | 티트리 추출물 및 소금을 포함하는 화장료 조성물 | |
EP3777872B1 (fr) | Compositions comprenant un extrait de graines de citrus junos et un extrait de riz brun et leurs utilisations | |
JP5414137B2 (ja) | ヒアルロニダーゼ活性阻害剤 | |
KR20130079683A (ko) | 폴리라이신 및 아연 피리치온을 포함하는 항진균 조성물 | |
KR102571226B1 (ko) | 글루코노락톤 및 클림바졸을 유효성분으로 포함하는 두피 상태 개선용 조성물 | |
RU2780260C1 (ru) | Средство косметического использования для кожи |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14901101 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/07/2017) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14901101 Country of ref document: EP Kind code of ref document: A1 |